Income statement, balance sheet and cash flow statement for the last 10 fiscal years, taken from the XBRL data Atara Biotherapeutics, Inc. files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2016
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Revenue
63.6
8.57
129
121
Research and development
56.5
81.2
167
216
245
282
273
225
151
37.4
General and administrative
24.7
40.3
69.7
79.6
64.4
78.8
71.6
50.9
39.9
26.3
Operating expenses
81.2
122
237
296
309
361
344
Operating income
-81.2
-122
-237
-296
-309
-340
-281
-276
-83.4
35.9
Interest expense
0.37
5.29
4.62
3.79
Other non-operating income
2.2
2.03
6.37
4.72
2.45
0.37
-0.7
-0.25
0.53
-0.03
Pre-tax income
-79
-120
-231
-291
-307
-340
-228
-276
-85.4
32.7
Income tax
0.01
-0.01
-0.04
0.01
0.02
0.05
0.01
0.02
-0.01
0.03
Net income
-79
-119
-231
-291
-307
-340
-228
-276
-85.4
32.7
EBITDA
-80.9
-121
-233
-289
-301
-331
-275
-271
-78.4
38
EPS, basic
-68.69
-99.91
-131.63
-141.62
-103.66
-90.67
-55.95
-65.19
-11.41
2.61
EPS, diluted
-68.69
-99.91
-131.63
-141.62
-103.66
-90.67
-55.95
-65.19
-11.41
2.57
Shares, basic (weighted)
1.15
1.2
1.75
2.05
2.96
3.75
4.08
4.24
7.49
12.5
Shares, diluted (weighted)
1.15
1.2
1.75
2.05
2.96
3.75
4.08
4.24
7.49
12.7
Balance sheet
FY2016
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Cash and equivalents
48
79.2
60.7
74.3
200
106
92.9
25.8
25
8.48
Short-term investments
208
86.9
249
185
300
265
150
25.9
17.5
0
Receivables
0
1.25
0.99
40.2
34.1
1.48
1.25
Inventory
0
1.59
9.71
10.7
0
Other current assets
4.68
5.9
11.7
13.7
21.2
12.4
10.3
6.18
10.1
2.48
Total current assets
261
172
321
273
523
385
295
102
64.9
12.2
Property, plant and equipment
3.26
44.1
68.6
54.2
50.5
53.8
6.3
3.86
1.29
0.07
Lease right-of-use assets
0
14
12.3
26.2
68
54.9
39.8
7.06
Other non-current assets
0.1
0.26
0.57
0.57
0.83
2.37
7.02
4.84
3.1
0.89
Total assets
264
218
392
343
588
468
376
166
109
20.2
Accounts payable
2.78
14.7
3.72
7.96
7.12
17.4
6.87
3.68
4.37
0.13
Accrued liabilities
3.75
5.66
5.63
3.9
3.02
5.96
7.44
19
6.03
1.8
Deferred revenue
33.5
77.8
Total current liabilities
9.68
27.6
40
36.7
82.9
106
78.9
142
135
14.9
Lease liabilities
0
14.1
13
25.5
58.1
45.7
29.9
9.35
Other non-current liabilities
13
1.28
2.04
1.5
5.56
4.63
3.27
1.8
Total liabilities
10.2
39.9
53
52.2
126
189
250
265
206
58.7
Paid-in capital
431
475
867
1,109
1,587
1,745
1,822
1,870
1,957
1,983
Retained earnings
-177
-297
-527
-818
-1,125
-1,465
-1,693
-1,969
-2,055
-2,022
Other comprehensive income
-0.18
-0.15
-0.34
0.22
0.3
-0.37
-2.07
-0.2
0.01
0
Shareholders' equity
254
178
339
291
462
280
127
99.2
-97.3
-38.5
Total equity
254
178
339
291
462
280
127
99.2
-97.3
-38.5
Total liabilities and equity
264
218
392
343
588
468
376
166
109
20.2
Shares outstanding
1.16
1.23
1.84
2.27
3.34
3.67
3.84
4.26
5.86
7.32
Cash flow statement
FY2016
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Net income
-79
-119
-231
-291
-307
-340
-228
-276
-85.4
32.7
Depreciation and amortization
0.38
0.96
3.73
7.07
8.33
9.35
5.65
4.83
5.05
2.12
Stock-based compensation
16.8
23.1
33.8
51.7
51.4
53.9
53.8
45.4
27
9.75
Deferred income tax
0
0
Change in receivables
0
0
-1.25
0.26
-39.2
6.11
32.6
0.23
Change in inventory
0
0
-1.59
-8.12
-4.43
10.7
Change in payables
0.98
2.16
-1.96
4.21
-0.82
9.07
-9.21
-3.13
0.69
-4.24
Cash from operations
-60
-87.5
-180
-236
-181
-221
-270
-193
-68.7
-50.9
Capital expenditures
-3.02
-20.2
-35.9
-5.73
-4.51
-10.6
-4.19
-1.22
-0.25
0
Purchases of investments
-305
-176
-466
-270
-426
-301
-181
-83.6
-19.7
-7.89
Cash from investing
83.7
99.9
-196
60.5
-121
22.3
203
124
8.62
18.1
Stock issued
0
19.2
47.6
47.7
69.2
98.7
21.9
2.14
9.35
1.47
Cash from financing
0.51
20
358
189
428
104
53.1
2.01
59.3
16.1
Net change in cash
24.2
31.3
-18.5
13.6
126
-94.3
-14.4
-67.1
-0.81
-16.7
Free cash flow
-63
-108
-216
-241
-185
-231
-275
-194
-69
-50.9
Interest paid
0
0
0.24
0.05
0.06
0.03
0.34
0.45
0.69
0.29
Income taxes paid
0.01
0
0
0
0.01
0.02
0.02
0
0.02
0.19
Key metrics
Worked out from the statements above. Latest values use the trailing twelve months to June 30, 2026; growth uses fiscal years. Valuation uses the share price of $8.81 on September 25, 2026.
Profitability
Metric
Value
How it is calculated
Operating margin
-229.7%
Operating income / revenue.
EBITDA margin
-227.6%
EBITDA (operating income + depreciation and amortization) / revenue.
Pre-tax margin
-269.0%
Pre-tax income / revenue.
Net margin
-269.4%
Net income / revenue.
Operating cash flow margin
-353.5%
Cash from operations / revenue.
Return on assets (ROA)
-79.4%
Net income / average total assets.
R&D / revenue
68.0%
Research and development expense / revenue.
Stock-based pay / revenue
62.7%
Stock-based compensation (from the cash flow statement) / revenue.
D&A / revenue
2.1%
Depreciation and amortization / revenue.
Growth
Metric
Value
How it is calculated
Revenue growth, 1y
-6.3%
Revenue vs the same period a year earlier. Only from a positive base.
Revenue CAGR, 3y
23.9%
Compound annual growth of revenue over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets growth, 1y
-81.5%
Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y
-62.3%
Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y
-49.0%
Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Share count change, 1y
69.8%
Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y
46.0%
Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 5y
33.8%
Change in diluted weighted shares, per year over 5 years. Negative means buybacks shrank the share count; positive means dilution.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
1.98x
Current assets / current liabilities.
Quick ratio
1.49x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
1.44x
(Cash + short-term investments) / current liabilities.
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
Revenue per share
$0.41
Revenue / diluted weighted shares.
Operating cash flow per share
-$1.46
Cash from operations / diluted weighted shares.
Book value per share
-$3.92
Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Market cap + total debt - cash - short-term investments.
P/S
14.3x
Market cap / revenue.
EV/Sales
12.7x
Enterprise value / revenue.
Earnings yield
-18.9%
Net income / market cap (the inverse of P/E).
What was Atara Biotherapeutics, Inc.'s revenue in fiscal 2025?
Atara Biotherapeutics, Inc. reported revenue of $120.8M for fiscal 2025, 6.3% lower than the year before.
Was Atara Biotherapeutics, Inc. profitable in fiscal 2025?
Yes. Net income was $32.7M, a net margin of 27.1%.
How much free cash flow did Atara Biotherapeutics, Inc. generate in fiscal 2025?
Cash from operations of $50.9M minus capital expenditures of $0.0 left free cash flow of -$50.9M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.